Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 21 July 2017 | By Michael Mezher
The European Medicines Agency (EMA) on Friday recommended the approval of eight new medicines after its Committee for Medicinal Products for Human Use (CHMP) met to discuss the drugs earlier this week.
The agency also issued negative opinions for Nektar and Daiichi Sankyo's breast cancer drug Onzeald (etirinotecan pegol) and Vanda Pharmaceuticals' schizophrenia drug Fanaptum (iloperidone).
Among the eight new medicines are five orphan medicines, including Santen Pharmaceutical's Verkazia (ciclosporin), which was given an accelerated assessment for severe vernal keratoconjunctivitis.
The four other orphan medicines include:
In its negative opinion for Fanaptum, EMA said the drug showed only modest short-term effectiveness and raised heart safety concerns that were "not manageable by the risk-minimisation measures proposed by the company."
And, in its negative opinion for Onzeald, EMA said the benefit of the drug was not sufficiently proven, due to data from a subgroup analysis not being supported by additional studies.
The agency also issued positive recommendations for Roche's Tecentriq (atezolizumab) in urothelial carcinoma and non-small cell lung cancer, Regeneron Pharmaceuticals' Dupixent (dupilumab) to treat atopic dermatitis and Janssen-Cilag's four-drug HIV combination Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide).
EMA also recommended generics for two drugs, including two copies of Bristol-Myers Squibb's hepatitis B drug Baraclude (entecavir) by Acord and Mylan, as well as Accord's copy of UCB's epilepsy drug Vimpat (lacosamide).
In addition, EMA recommended extending the indication of eight drugs, including Bydureon (exenatide), Gazyvaro (obinutuzumab), Humira (adalimumab), Keytruda (pembrolizumab), RoActemra (tocilizumab), Signifor (pasireotide), Sovaldi (sofosbuvir) and Vimpat.
EMA
Tags: CHMP
Regulatory Focus newsletters
All the biggest regulatory news and happenings.